Posttransplant complications in patients with prior CD19-targeted CAR-T treatment
| . | ALL (n = 19) . | NHL/CLL (n = 13) . | Entire cohort (N = 32) . |
|---|---|---|---|
| Acute GVHD | |||
| Grade 1 | 2 (10.5) | 1 (7.7) | 3 (9.4) |
| Grade 2 | 8 (42.1) | 6 (46.2) | 14 (43.8) |
| Grade 3 | 3 (15.8) | 2 (15.4) | 5 (15.6) |
| Grade 4 | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| 1-y cumulative incidence of grade 2-4 (95% CI), % | 63 (40-86) | 77 (51-100) | 69 (52-85) |
| 1-y cumulative incidence of grade 3-4 (95% CI), % | 21 (2-40) | 31 (4-57) | 25 (10-40) |
| Chronic GVHD | |||
| No | 15 (78.9) | 12 (92.3) | 27 (84.4) |
| Yes | 4 (21.1) | 1 (7.7) | 5 (15.6) |
| 1-y cumulative incidence (95% CI), % | 16 (0-33) | 0 (0-0) | 10 (0-21) |
| Viral and fungal infections | |||
| Parainfluenza | 2 (10.5) | 0 (0.0) | 2 (6.2) |
| HSV-1 stomatitis | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Adenovirus hepatitis | 1(5.3) | 0 (0.0) | 1 (3.1) |
| CMV gastroenteritis | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| RSV | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Aspergillosis | 3 (15.8) | 0 (0.0) | 3 (9.4) |
| Other fungal | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| Toxoplasmosis | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Nonhematologic toxicities | |||
| Neurologic: PRESS | 1 (8) | 0 (0) | 1 (3) |
| Cardiac: atrial fibrillation | 1 (5) | 1 (8) | 2 (6) |
| Hepatic: cholecystitis | 1 (5) | 0 (0) | 1 (3) |
| Renal: TMS | 0 (0) | 3 (23) | 3 (9) |
| Renal: other renal | 2 (10.5) | 0 (0) | 2 (6) |
| GI: bleeding | 0 (0) | 1 (8) | 1 (3) |
| Pulmonary: DAH | 2 (10.5) | 1 (8) | 3 (9) |
| Pulmonary: PE | 0 (0) | 1 (8) | 1 (3) |
| Cause of death | |||
| Disease progression | 2 (10.5) | 2 (15.4) | 4 (12.5) |
| GVHD | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| Fungal infection | 1 (5.3) | 1 (7.7) | 2 (6.2) |
| Sepsis | 1 (5.3) | 0 | 1 (3.1) |
| Pulmonary | |||
| PE | 0 | 1 (7.7) | 1 (3.1) |
| IPS | 1 (5.3) | 0 | 1 (3.1) |
| Total | 6 (31) | 6 (46) | 12 (37.5) |
| . | ALL (n = 19) . | NHL/CLL (n = 13) . | Entire cohort (N = 32) . |
|---|---|---|---|
| Acute GVHD | |||
| Grade 1 | 2 (10.5) | 1 (7.7) | 3 (9.4) |
| Grade 2 | 8 (42.1) | 6 (46.2) | 14 (43.8) |
| Grade 3 | 3 (15.8) | 2 (15.4) | 5 (15.6) |
| Grade 4 | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| 1-y cumulative incidence of grade 2-4 (95% CI), % | 63 (40-86) | 77 (51-100) | 69 (52-85) |
| 1-y cumulative incidence of grade 3-4 (95% CI), % | 21 (2-40) | 31 (4-57) | 25 (10-40) |
| Chronic GVHD | |||
| No | 15 (78.9) | 12 (92.3) | 27 (84.4) |
| Yes | 4 (21.1) | 1 (7.7) | 5 (15.6) |
| 1-y cumulative incidence (95% CI), % | 16 (0-33) | 0 (0-0) | 10 (0-21) |
| Viral and fungal infections | |||
| Parainfluenza | 2 (10.5) | 0 (0.0) | 2 (6.2) |
| HSV-1 stomatitis | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Adenovirus hepatitis | 1(5.3) | 0 (0.0) | 1 (3.1) |
| CMV gastroenteritis | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| RSV | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Aspergillosis | 3 (15.8) | 0 (0.0) | 3 (9.4) |
| Other fungal | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| Toxoplasmosis | 1 (5.3) | 0 (0.0) | 1 (3.1) |
| Nonhematologic toxicities | |||
| Neurologic: PRESS | 1 (8) | 0 (0) | 1 (3) |
| Cardiac: atrial fibrillation | 1 (5) | 1 (8) | 2 (6) |
| Hepatic: cholecystitis | 1 (5) | 0 (0) | 1 (3) |
| Renal: TMS | 0 (0) | 3 (23) | 3 (9) |
| Renal: other renal | 2 (10.5) | 0 (0) | 2 (6) |
| GI: bleeding | 0 (0) | 1 (8) | 1 (3) |
| Pulmonary: DAH | 2 (10.5) | 1 (8) | 3 (9) |
| Pulmonary: PE | 0 (0) | 1 (8) | 1 (3) |
| Cause of death | |||
| Disease progression | 2 (10.5) | 2 (15.4) | 4 (12.5) |
| GVHD | 1 (5.3) | 2 (15.4) | 3 (9.4) |
| Fungal infection | 1 (5.3) | 1 (7.7) | 2 (6.2) |
| Sepsis | 1 (5.3) | 0 | 1 (3.1) |
| Pulmonary | |||
| PE | 0 | 1 (7.7) | 1 (3.1) |
| IPS | 1 (5.3) | 0 | 1 (3.1) |
| Total | 6 (31) | 6 (46) | 12 (37.5) |
Unless otherwise indicated, data are n (%).
CMV, cytomegalovirus; DAH, diffuse alveolar hemorrhage; GI, gastrointestinal; HSV, herpes simplex virus; IPS, idiopathic pulmonary syndrome; PE, pulmonary embolus; PRESS, posterior reversible encephalopathy syndrome; RSV, respiratory syncytial virus.